Lian Brian's Form 4 filing
Viking Therapeutics, Inc. (VKTX) · filed Apr 18, 2023
- Accession no.
- 0001209191-23-024724
- Filed
- Apr 18, 2023
- Trade date
- Apr 17, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.17M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lian BrianCIK 0001614578 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock, par value $0.00001 per share | MOption exerciseAcquired | +125,000 | $2.15 | +$268,750 | 2,432,963 | Direct | |
| Apr 17, 2023 | Common Stock, par value $0.00001 per share | SSaleDisposed | −155,000 | $20.45 | −$3,169,750 | 2,277,963 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2023 | Common Stock | MOption exerciseDisposed | −125,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.